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3'-Azido-2',3'-deoxythymidine and carbovir [racemic and (-) enantiomerl were evaluated individually and
in combination for antiviral activity against human immunodeficiency virus type 1 replication and cytotoxicity
in vitro. The combination of these drugs synergistically inhibited human immunodeficiency virus type 1
replication in C3 and Jurkat cells and in human peripheral blood mononuclear cells, although the saihe
combination also produced synergistic cytotoxicity in human peripheral blood mononuclear cells.
The only agents approved for the treatment of human
immunodeficiency virus type 1 (HIV-1) infections are 3'-
azido-2',3'-deoxythymidine (AZT) (7, 11, 12), 2',3'-dideox-
yinosine (2, 21), and 2',3'-dideoxycytidine. The primary
mode of action of AZT triphosphate is to competitively
inhibit reverse transcriptase and to act as a chain terminator
of DNA synthesis (18). Despite documented efficacy in
patients, the adverse side effects of AZT (14) and the
recovery of multiple strains of AZT-resistant HIV-1 (10)
from AZT-treated patients also accentuate the need for
alternative strategies for therapy for HIV-1 infections. Com-
bination drug therapy may alleviate the toxicity burden of
chemotherapy for the patient as a result of a synergistic
antiviral response, allowing both drugs to be used at con-
centrations lower than if used independently. In this paper,
we report the effect of in vitro combination drug treatment
with (-)-carbovir and AZT (3, 20) on the inhibition of HIV-1
replication. Although the mechanism of action remains un-
resolved, our results indicate a strong, synergistic inhibition
of HIV-1 replication in primary human peripheral blood
mononuclear cells (HPBMCs) and in some human T-cell
lines.
(Portions of this work were previously presented [16].)
HPBMCs used in these studies were isolated from four
HIV-negative donors and were grown in RPMI 1640 medium
with 10% human type AB serum or 20% fetal bovine serum,
penicillin (100 IU/ml), streptomycin (100 p,g/ml), and L-glu-
tamine (2 mM) (GIBCO, Grand Island, N.Y.). The HPBMCs
were stimulated in culture for 24 h with 2.5 ,ug of phytohe-
magglutinin per ml (Burroughs Wellcome, Research Triangle
Park, N.C., or Sigma, St. Louis, Mo.) followed by 10
Biological Response Modifiers Program units or 4 U of
recombinant interleukin 2 per ml (Genzyme, Boston, Mass.,
or Boehringer Mannheim, Indianapolis, Ind.). The HPBMCs
were infected with 0.01 50% tissue culture infective dose unit
of human T-cell leukemia virus IIIb (HTLV-IIIb; gift of
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R. C. Gallo, National Institutes of Health, Bethesda, Md.) or
with a patient virus isolate (15a) which was partially resistant
to AZT in comparison with sensitive isolates (50% effective
concentration [EC5O] = 160 versus 5 nM, respectively) when
tested in MT2 cells (EC50s differ from those derived in
HPBMCs). The human T-cell lines H9, C3, and Jurkat were
grown and infected as previously described (17).
The evaluation of drug synergy was designed in two
different ways. One method employed checkerboard exper-
iments, evaluating both racemic or (-)-carbovir and AZT for
anti-HIV activity individually and in combination. The other
design employed dilutions of constant ratios of drugs (5),
analyzing the dose-effect relationships by the median effect
equation (4). Combination indices were not calculated from
data when the fraction affected (Fa) is >0.98. The more
conservative mutually nonexclusive combination indices
were used in addition to isobolograms for EC50, EC70, and
EC90 levels to depict synergism of combined drug effects (6).
Additive interactions were calculated with the Loewe and
Webb equations in the three-dimensional method of plotting
checkerboard design inhibition experiments to show antag-
onism or synergism of drugs (summarized in reference 13).
In addition to evaluating the antiviral efficacy of the drug
combinations, we evaluated the cytotoxicity potential of this
approach by using a dye conversion-cell viability assay (1).
The uninfected cells were incubated in the presence of the
TABLE 1. Antiviral activities of (-)-carbovir and AZT in
primary HPBMCs infected with HTLV-IIIb
(-)-Carbovir (ILM) AZT (>tM)Expt no.
EC50 EC90 EC50 EC90













Mean SDa 0.1 0.046 0.875 + 0.25 0.0035 0.003 0.0625 + 0.025
a Values are means standard deviation (SD) of four experiments per-
formed with three replicates.
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TABLE 2. Combination indices for AZT and (-)-carbovir on
HPBMCs infected with HTLV-IIIb
(-)-Carbovir AZT Total AZT/(-)- Combination
(I1M) (AM) dose carbovir Fa index(ILM) ratio
o o 0 0
0.05 0 0.05 0.35
0.10 0 0.10 0.49
0.20 0 0.20 0.62
0.50 0 0.50 0.81
1.00 0 1.00 0.91
0 0.0005 0.0005 0.34
0 0.001 0.001 0.66
0 0.01 0.01 0.84
0 0.05 0.05 0.91
0.05 0.001 0.051 1:50 0.79 0.29
0.10 0.001 0.101 1:100 0.83 0.31
0.20 0.001 0.201 1:200 0.90 0.26
0.50 0.001 0.501 1:500 0.93 0.41
1.00 0.001 1.001 1:1,000 0.97 0.30
0.05 0.01 0.06 1:5 0.89 0.51
0.10 0.01 0.11 1:10 0.94 0.23
0.20 0.01 0.21 1:20 0.96 0.15
0.50 0.01 0.51 1:50 0.98 0.10
1.00 0.01 1.01 1:100 0.99 a
0.05 0.05 0.10 1:1 0.97 0.27
0.10 0.05 0.15 1:2 0.97 0.32
0.20 0.05 0.25 1:4 0.99
0.50 0.05 0.55 1:10 0.99
a -, Fa values too high to be evaluated.
highest concentrations of the drugs tested, individually and
in combination, with an initial dose of the drug(s) for a period
of 7 days.
The antiviral activities of racemic or (-)-carbovir and
AZT were evaluated for EC50 and EC90 values in HPBMCs
(Table 1). The inhibitory concentrations were reduced when
the two drugs were used in combination (Table 2). Figure 1
shows the effect of increasing amounts of the two drugs on
virus production as assayed by reverse transcriptase activity
in HPBMCs. The concentrations of (-)-carbovir and AZT
resulting in a 90% inhibition of the reverse transcriptase
activity (EC9O) were used to construct isobolograms (not
shown), which indicated a strong pattern of synergy. The
data were also analyzed according to the derived combina-
tion index values (data not shown). The values obtained
ranged from 0.10 to 0.51, indicating strong synergism be-
tween AZT and (-)-carbovir in HPBMCs.
These data were complemented in a checkerboard design
experiment with primary HPBMCs infected with a fresh
patient HIV-1 isolate which was partially AZT resistant
(data not shown). The actual fraction affected was compared
to the Fa calculated for additivity by the equations of Loewe
and Webb. In every case (25 combinations), the Fa exceeded
the inhibition predicted for additivity by both equations
(except where the Loewe equation predicts >100% inhibi-
tion), again suggesting synergy of the two drugs in primary
human cells. By the Chou combination index method, the
conservative mutually exclusive combination indices calcu-
lated from the same data also indicated synergy of the two
drugs against HIV-1 infection; the replication of AZT-resis-
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FIG. 1. HIV-1 replication in primary HPBMCs as a function of
combinations of (-)-carbovir and AZT. The reverse transcriptase
activity present in the cell-free culture supernatants of HPBMCs
infected with HTLV-IIIb was determined after 7 days of incubation.
The untreated control value of 18,533 cpm of reverse transcriptase
activity represents the activity in 6 ml of culture supematant. 0,
control; *, 0.5 nM AZT; A, 1 nM AZT; V, 10 nM AZT; *, 50 nM
AZT. The error bars represent the standard error of the mean values
of three replicate samples.
Combination studies were performed with constant molar
ratios of 1:1 or 1:5 (AZT-carbovir) in two experiments with
Jurkat cells infected with the LAV isolate of HIV-1. The
mutually nonexclusive combination indices were calculated
from the data (not shown) by using the Chou and Chou
software (4), with values ranging from 0.37 to 0.76 (for a total
of 11 combinations), indicating a synergistic relationship
between (-)-carbovir and AZT. Synergistic antiviral activi-
ties were also observed with the racemic mixture of carbovir
and AZT in two constant ratios in an experiment using C3
cells infected with the LAV isolate. The combination indices
from constant molar ratios of 1:6 and 1:20 (AZT-carbovir)
range from 0.54 to 0.97 (for eight combinations). In contrast,
the inhibition of HIV-1 replication in H9 cells with combi-
nations of (-)-carbovir and AZT was shown to be an
additive relationship (data not shown). The H9 cell experi-
ments were performed with the checkerboard drug combi-
nation method and analyzed according to the isobologram
method of Elion et al. (6).
In parallel with the antiviral efficacy studies, the effect of
carbovir and AZT on the cytotoxicity to H9 and C3 cells and
HPBMCs was tested. No toxicity was noted for H9 or C3
cells (data not shown) with the highest concentrations (100
,uM) used for the antiviral assays, individually or in combi-
nation. For the HPBMCs, the drug combinations were
synergistically cytotoxic to HPBMCs at all combinations
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TABLE 3. Combination indices for (-)-carbovir and AZT on HPBMC cytotoxicity"
Treatment (-)-Carbovir AZT (>M) Total dose F. Combination
Treatment ~~~(P~M ~ M) (j±M) Faindex
AZT 0 100 100 0.74
0 50 50 0.62
0 25 25 0.49
0 10 10 0.42
(-)-Carbovir 100 0 100 0.78
50 0 50 0.56
25 0 25 0.41
10 0 10 0.19
1:1 (-)-carbovir-AZT 50 50 100 0.98 __b
25 25 50 0.72 0.24
12.5 12.5 25 0.54 0.36
6.25 6.25 12.5 0.16 1.16
3.125 3.125 6.25 0.23 0.85
1:5 (-)-carbovir-AZT 20 100 120 0.95 0.17
10 50 60 0.63 0.36
5 25 30 0.53 0.42
2.5 12.5 15 0.37 0.52
1.25 6.25 7.5 0.33 0.56
100:1 (-)-carbovir-AZT 10 0.1 10.1 0.44 0.27
5 0.05 5.05 0.29 0.34
2.5 0.025 2.525 0.10 0.68
0.625 0.00625 0.63125 0.17 0.47
0.3125 0.003125 0.315625 0.20 0.43
aResults of representative experiment from four assays performed in triplicate.
b Fa value too high to be evaluated.
tested by the Chou method (Table 3). However, the degree
of cytotoxicity observed was 30% or less at the concentra-
tions which elicited the maximum antiviral effect [0.1 to 1
,uM (-)-carbovir combined with 10 to 50 nM AZT; F, >
0.94].
Carbovir [racemic or the (-) enantiomer] and AZT are
active inhibitors of HIV-1 replication in vitro (3, 11, 12, 19).
As reported by Shannon (15), we found synergistic inhibition
of HIV-1 by this combination of drugs in various cell types.
Shannon has shown synergistic relationships between the
racemic mixture of carbovir and other antiviral agents (in
combination with ribavirin or AZT in human T-cell lines
MT-2, ATH-8, and CEM). Because the biologically active
species is (-)-carbovir (3), we focused on the antiviral
activity associated with this enantiomer and found that the
pure, active enantiomer of carbovir is synergistic with AZT
in primary HPBMCs.
The T-cell lines tested did not exhibit cytotoxicity with the
drug combinations tested, but there was synergistic toxicity
of the drug combination to HPBMCs. Synergistic cytotox-
icity of the drugs was present at each ratio and at each total
drug concentration examined. A comparison of the ratios
and concentrations of the drugs used to elicit strong syner-
gistic inhibition of the HIV replication (Fig. 1) to the
cytotoxicity data showed that the 10:1 ratio [(-)-carbovir-
AZT; total drug concentration, 0.11 p,M] had an antiviral F.
of 94% and a predicted cytotoxicity F, of <30%. These data,
combined with marginal synergistic toxicity in human bone
marrow progenitor cells (data not shown; 8), may indicate
that the enhanced antiviral effects observed with this com-
bination could be due in part to cellular cytotoxicity. These
findings also raise concerns about concurrent clinical use of
these agents.
We have found that (-)-carbovir and AZT act synergisti-
cally to inhibit the replication of HIV-1, although they are
also synergistically cytotoxic to primary HPBMCs. Further
studies are needed to evaluate the benefits on antiviral
effects realized from the combined drug treatments in con-
trast to the potential for enhanced toxic effects.
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